13F Holdings
中文EN

ZVRA ZEVRA THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1434647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY75.1%
TTM net income YoY120.8%
TTM EPS YoY159.6%
Revenue 3-yr CAGR106.2%
Net income 3-yr CAGR—

Margins

Gross margin95.4%
Operating margin60.8%
Net margin52.8%
FCF margin25.9%
EBITDA margin61.8%

Returns

ROE41.9%
ROA26.7%
ROIC (approx.)60.6%
Asset turnover0.51x

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio5.46x
Interest coverage24.55x

Cash quality & payout

Operating cash flow / net income0.50x
Accruals ratio13.5%
Payout ratio—
Capex / revenue0.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$106.47M$23.61M$27.46M$10.16M$28.65M
Cost of revenue$16.48M$7.42M$2.17M$222,000$2.06M
Gross profit$89.99M$16.20M$25.29M$9.94M$26.59M
R&D expense$12.74M$42.09M$39.81M$19.80M$10.16M
SG&A expense$77.62M$54.87M$34.31M$15.04M$8.70M
Operating income-$62.94M-$87.00M-$49.60M-$42.56M$7.73M
Interest expense$7.98M$7.35M$1.50M$335,000$226,000
Pretax income$86.68M-$90.14M-$46.05M-$26.80M-$8.52M
Income tax$3.45M$15.37M$0-$33,000$34,000
Net income$83.23M-$105.51M-$46.05M-$26.77M-$8.55M
EBITDA-$58.89M-$80.61M-$48.60M-$41.62M$7.99M
EPS (basic)1.40-2.28-1.30-0.78-2.11
EPS (diluted)1.35-2.28——-2.11
Weighted avg. shares (diluted)57.26M46.25M——29.77M
Balance sheet
Cash & equivalents$62.41M$33.78M$43.05M$65.47M$112.35M
Short-term investments$128.60M$35.71M$24.69M$16.90M$0
Receivables—$10.18M$16.12M$7.18M$1.42M
Inventory$1.74M$1.97M$0$671,000—
Current assets$223.01M$86.03M$86.94M$92.83M$115.06M
PP&E, net$489,000$356,000$736,000$794,000$884,000
Goodwill$4.70M$4.70M$4.70M$0—
Intangibles$6.42M$68.99M$69.23M$0—
Total assets$284.73M$178.13M$172.33M$115.34M$132.94M
Current liabilities$39.28M$34.06M$73.72M$12.02M$4.23M
Long-term debt$61.93M$59.50M$5.07M——
Total debt$61.93M$59.50M$5.07M——
Total liabilities$130.07M$138.46M$110.46M$40.22M$5.82M
Shareholders' equity$154.66M$39.67M$61.86M$75.12M$101.66M
Net debt-$478,000$25.72M-$37.98M——
Shares outstanding56.85M53.67M41.53M34.54M35.01M
Cash flow statement
Operating cash flow-$1.60M-$69.67M-$33.53M-$18.72M$10.44M
Capital expenditure$835,000$0$296,000$93,000$102,000
Free cash flow-$2.43M-$69.67M-$33.83M-$18.81M$10.34M
Investing cash flow$18.13M-$22.16M-$17.39M-$36.72M-$15.52M
Financing cash flow$12.06M$82.11M$28.46M$8.35M$113.11M
Depreciation & amortization$4.05M$6.39M$1.01M$944,000$257,000
Stock-based compensation$12.63M$14.91M$5.95M$4.29M$2.44M
Share buybacks—$0$3.45M$4.72M$2.81M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.